University of South Florida

Alabama State University

Arun Babu Kumar

Shyam S Mohapatra

Ashok Kumar

Don F Cameron

Shree R Singh

Souheil Zekri

Bishwabhusan Sahoo

Roman Manetsch

Susana Lai-Yuen

Parshuram Balkrishna Zantye

Jeremiah Dwayne Tipton

Anna K Parsons

Sumita Behera

Natasha Faith Cover

A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the injected nanoparticle load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection.

Nanoparticle targeted drug delivery to the lungs using extra-testicular sertoli cells

Provided herein are pyridyl- and pyrimidyl-containing diazirines that can be photoactivateable probes and formulations thereof. Also provided herein are photoaffinity labels that can include the pyridyl- and pyrimidyl-containing diazirines provided herein. Also provided herein are methods of using the photoactivatable probes and photoaffinity labels provided herein in a photoaffinity labeling reaction and/or assay.

Photoactivatable probes and uses thereof

A device and method for the collection of sterile specimen samples from the uterus is presented. Also presented is a method of delivering nano-encapsulated drugs to the female reproductive tract to treat pelvic inflammatory disease. The device generally is comprised of an outer cannula over which a cover is provided. A sampler may be positioned within the cannula so that when the sampler is advanced through the cannula, the sampler exits an orifice at one end of the cannula and pierces the cover causing it to retract. In use, the device is positioned within the vagina and once correctly positioned, the sampler is advanced thus piercing the cover and allowing an uncontaminated sample to be taken from the uterus or a drug to be delivered directly into the uterus.

Device for sterile uterine sampling and drug delivery

Nanoparticle targeted drug delivery to the lungs using extra-testicular Sertoli cells

A drug delivery device has been designed to directly deliver an agent to the ovaries through direct contact with the fallopian tubes. The device consists of three main components: a tubular inserter, a cylindrical chamber and a plunger. The device is a single-use applicator designed in a shape similar to a tampon to facilitate its insertion through the vagina and into the uterus. Positioning of the device centrally in the uterus is accomplished through the use of ultrasound. The chamber is inserted into the tubular inserter. Adjusting the length of the chamber inserted into the tubular inserter controls the amount of tubing released from the apertures in the tubular inserter. Ultrasound is used to ensure the proper placement of each tube at the entrance of each fallopian tube. The plunger is inserted into the chamber and adjustment of the plunger controls the amount of the agent released into the tubes.

Drug delivery device for ovarian cancer

The subject invention concerns materials and methods for detecting nucleic acid sequences. One aspect of the invention concerns a silicon-based 'biochip' comprising nucleic acid immobilized thereon. In one embodiment, the silicon comprises microcavities. The nucleic acid to be assayed for the presence of one or more target nucleic acid sequences is immobilized on the silicon. A nucleic acid, such as an oligonucleotide probe, having a sequence substantially complementary to the target nucleic acid sequence can be used to detect the immobilized nucleic acid on the silicon. If the nucleic acid used for detection hybridizes with a target nucleic acid sequence, the hybridized sequences can be detected directly or indirectly. In an exemplified embodiment, the oligonucleotide probe can be labeled with a detectable label, for example, a fluorescent molecule. The subject invention also concerns methods for detecting a target nucleic acid using a silicon-based biochip of the invention.

DNA biochip and methods of use

Functionalized Single Wall Carbon Nanotube (SWCNT) complexed with nanochitosan for use in the delivery of bioaffecting substances and diagnostic applications. fSWCNT complexed with the chitosan NG042 were used for delivery of DNA-encoding EGFP reporter protein and peptide. The results demonstrate that shown CNT-chitosan hybrid nanoparticles exhibit significantly higher transfection efficiency in vivo than chitosan alone. Furthermore, the functionalized nanotubes were tested for peptide transfer into HEK293 cells. The results showed that the hybrid nanoparticles efficiently transferred peptides. Together, these results show that hybrid SWCNT-chitosan particles increase DNA and peptide transfer into cells.

Method of drug delivery by carbon nanotube-chitosan nanocomplexes

A method of transdermal drug delivery using drug formulations and other small molecules is described. The drug or other small molecule formulation is applied to the skin of a patient using a radio frequency device. The radio frequency device facilitates the ablation of the stratum corneum allowing the drug or other small molecule to pass to the underlying skin. The drug or small molecule can be contained in hyaluronic acid nanoparticles or suspended in a gel.

Method of transdermal drug delivery

The present invention pertains to a nano-based sensing device (a sensor) comprising a nano-scale working electrode that can be used for the ultra-sensitive detection of blood analytes, disease biomarkers, and other target molecules. The present invention also pertains to a method for detecting target molecules using the sensor as the sensor element of a microfluidic device.

Nano-based device for detection of disease biomarkers and other target molecules

The proposed slurry can be used to planarize polymeric candidate ILD materials such Benzocylobutene (BCB), SILK, Polyimide, etc. The slurry consists of colloidal suspension of nanoparticle abrasives made up of Tetraethylorthosilicate (TEOS)-derived silica and Zirconium-dioxide (ZrO), its derivatives and any materials modified from ZrOand/or TEOS, in a chemically active medium. The base solution of the slurry consists of deionized (Dl) water, buffering agents like inorganic buffer comprised of inorganic acids such as TRIS-Hcl, its derivatives and variants, cleansing agents, surface modified catalysts, and surface reagents. The organic solvents like isopropyl alcohol, methanol, and other organic alcohols ranging from 0.0005 to 0.05% are employed for active dissolution of the chemical surface complex formed as a result of the slurry chemical action. The inorganic buffer is so chosen that the complex salts resulting from the reaction impart hydrophobicity to the polished thin film surface. The advantages of hydrophobicity include: a) reduced particle adhesion on surface, b) less intensive post-CMP clean, c) no surface degradation or contamination, etc.

CMP slurry for polymeric interlayer dielectric planarization

The present invention pertains to nanoparticles, comprising a metal and/or polymer core, with 7-alpha hydroxylase, or an enzymatically active fragment thereof, nicotinamide adenine dinucleotide (NADH) and antibodies, or antibody fragments, specific for low density lipoprotein (LDL), attached to the core. The invention also concerns methods for reducing LDL cholesterol in a human or animal subject by administering nanoparticles of the invention. In a preferred embodiment, both circulating LDL and plasma cholesterol levels are reduced in the subject.

Materials and methods to reduce low density lipoprotein cholesterol

The present invention relates to the development of a hyaluronic acid and hyaluronic acid hybrid nanoparticle systems for the administration of active molecules, peptides, DNA and/or other hydrophilic or hydrophobic molecules, the composition of hyaluronic acid and hyaluronic acid hybrid nanoparticle systems, and the procedure for their development and use. These nanoparticles are made up of hyaluronic acid in salt form, preferentially the sodium salt of the polymers or hybridized with magnetic Fe particles. The nanoparticles are basically from natural polymers, biocompatibles and biodegradables. The nanoparticles allow the controlled release of the active molecules they transport and their orientation towards the target tissues. The present invention teaches a procedure to elaborate particles of hyaluronic acid with a diameter less than 180 nm., that incorporate an active ingredient, independent of its hydrophilic or hydrophobic nature. Procedures to produce the particles are described. The present invention will be useful in methods of transdermal drug delivery using hyaluronic acid nanoparticles, among other uses.

Growing community of inventors

Bothell, WA, United States of America

Arun Babu Kumar